Four-year outcomes after transcatheter or contemporary surgical sortic valve replacement from the Evolut Low Risk trial

Authors

Basel Ramlawi, Cardiovascular Surgery, Lankenau Heart Institute, Philadelphia, PA. Electronic address: basel.ramlawi@gmail.com.
G Michael Deeb, Department of Cardiothoracic Surgery, University of Michigan Hospitals, Ann Arbor, MI.
Mubashir Mumtaz, Department of Cardiac Surgery, University of Pittsburgh Medical Center, Harrisburg, PA.
Tanvir Bajwa, Advocate Health - MidwestFollow
Joshua D. Rovin, Center for Advanced Valve and Structural Heart Care, Morton Plant Hospital, Clearwater, FL.
Steven J. Yakubov, Department of Interventional Cardiology, Riverside Methodist-OhioHealth, Columbus, OH.
Yoojin Jung, Structural Heart and Aortic, Medtronic, Minneapolis, MN.
Michael J. Reardon, Department of Cardiothoracic Surgery and Interventional Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX.
John K. Forrest, Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, CT.

Recommended Citation

Ramlawi B, Deeb GM, Mumtaz M, et al. Four-year outcomes after transcatheter or contemporary surgical aortic valve replacement from the Evolut Low Risk trial. J Thorac Cardiovasc Surg. 2025;170(1):e16-e26. doi:10.1016/j.jtcvs.2024.08.023

Affiliations

Aurora St. Luke's Medical Center

Type

Article

PubMed ID

39181441